Abstract
BACKGROUND. Caspofungin inhibits synthesis of β-1,3-glucan, an essential component of the Aspergillus cell wall. This echinocandin has demonstrated efficacy (45% success) as salvage monotherapy of invasive aspergillosis (IA). Interest remains as to whether caspofungin, in combination with other antifungal classes, can improve the efficacy against IA. METHODS. The study involved 53 adults with documented IA who were refractory to or intolerant of standard antifungal therapy and received caspofungin and 1 other mold-active antifungal agent (at the investigator's discretion). Efficacy was assessed by signs, symptoms, and radiographs at the end of combination therapy and Day 84 after combination therapy initiation. Favorable (complete or partial) responses required significant clinical and radiographic improvement. Diagnoses and outcomes were assessed by an independent expert. RESULTS. Among the 53 patients enrolled the most common underlying diseases were acute leukemia (53%), lymphoma (11%), and chronic leukemia (6%). Pulmonary aspergillosis (81%) was the most common site, and most patients (87%) were refractory to prior therapy. Success at the end of combination therapy and Day 84 was 55% (29/53) and 49% (25/51), respectively. Fifty-seven percent of patients with neutropenia and 54% who received an allogeneic hematopoietic stem cell transplant responded favorably. Survival at Day 84 was 55%. Combination therapy, dosed on average for 31.3 days, was well tolerated. Two (4%) serious drug-related adverse events, both attributed to voriconazole, occurred. None of the patients discontinued caspofungin due to toxicity. CONCLUSION. Caspofungin in combination with a triazole or polyene was an effective alternative as salvage therapy for patients with recalcitrant Aspergillus infections.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2888-2897 |
| Number of pages | 10 |
| Journal | Cancer |
| Volume | 107 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 15 2006 |
Fingerprint
Keywords
- Aspergillosis
- Caspofungin
- Combination therapy
- Salvage therapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. / Maertens, Johan; Glasmacher, Axel; Herbrecht, Raoul; Thiebaut, Anne; Cordonnier, Catherine; Segal, Brahm H.; Killar, John; Taylor, Arlene; Kartsonis, Nicholas; Patterson, Thomas F.
In: Cancer, Vol. 107, No. 12, 15.12.2006, p. 2888-2897.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis
AU - Maertens, Johan
AU - Glasmacher, Axel
AU - Herbrecht, Raoul
AU - Thiebaut, Anne
AU - Cordonnier, Catherine
AU - Segal, Brahm H.
AU - Killar, John
AU - Taylor, Arlene
AU - Kartsonis, Nicholas
AU - Patterson, Thomas F
PY - 2006/12/15
Y1 - 2006/12/15
N2 - BACKGROUND. Caspofungin inhibits synthesis of β-1,3-glucan, an essential component of the Aspergillus cell wall. This echinocandin has demonstrated efficacy (45% success) as salvage monotherapy of invasive aspergillosis (IA). Interest remains as to whether caspofungin, in combination with other antifungal classes, can improve the efficacy against IA. METHODS. The study involved 53 adults with documented IA who were refractory to or intolerant of standard antifungal therapy and received caspofungin and 1 other mold-active antifungal agent (at the investigator's discretion). Efficacy was assessed by signs, symptoms, and radiographs at the end of combination therapy and Day 84 after combination therapy initiation. Favorable (complete or partial) responses required significant clinical and radiographic improvement. Diagnoses and outcomes were assessed by an independent expert. RESULTS. Among the 53 patients enrolled the most common underlying diseases were acute leukemia (53%), lymphoma (11%), and chronic leukemia (6%). Pulmonary aspergillosis (81%) was the most common site, and most patients (87%) were refractory to prior therapy. Success at the end of combination therapy and Day 84 was 55% (29/53) and 49% (25/51), respectively. Fifty-seven percent of patients with neutropenia and 54% who received an allogeneic hematopoietic stem cell transplant responded favorably. Survival at Day 84 was 55%. Combination therapy, dosed on average for 31.3 days, was well tolerated. Two (4%) serious drug-related adverse events, both attributed to voriconazole, occurred. None of the patients discontinued caspofungin due to toxicity. CONCLUSION. Caspofungin in combination with a triazole or polyene was an effective alternative as salvage therapy for patients with recalcitrant Aspergillus infections.
AB - BACKGROUND. Caspofungin inhibits synthesis of β-1,3-glucan, an essential component of the Aspergillus cell wall. This echinocandin has demonstrated efficacy (45% success) as salvage monotherapy of invasive aspergillosis (IA). Interest remains as to whether caspofungin, in combination with other antifungal classes, can improve the efficacy against IA. METHODS. The study involved 53 adults with documented IA who were refractory to or intolerant of standard antifungal therapy and received caspofungin and 1 other mold-active antifungal agent (at the investigator's discretion). Efficacy was assessed by signs, symptoms, and radiographs at the end of combination therapy and Day 84 after combination therapy initiation. Favorable (complete or partial) responses required significant clinical and radiographic improvement. Diagnoses and outcomes were assessed by an independent expert. RESULTS. Among the 53 patients enrolled the most common underlying diseases were acute leukemia (53%), lymphoma (11%), and chronic leukemia (6%). Pulmonary aspergillosis (81%) was the most common site, and most patients (87%) were refractory to prior therapy. Success at the end of combination therapy and Day 84 was 55% (29/53) and 49% (25/51), respectively. Fifty-seven percent of patients with neutropenia and 54% who received an allogeneic hematopoietic stem cell transplant responded favorably. Survival at Day 84 was 55%. Combination therapy, dosed on average for 31.3 days, was well tolerated. Two (4%) serious drug-related adverse events, both attributed to voriconazole, occurred. None of the patients discontinued caspofungin due to toxicity. CONCLUSION. Caspofungin in combination with a triazole or polyene was an effective alternative as salvage therapy for patients with recalcitrant Aspergillus infections.
KW - Aspergillosis
KW - Caspofungin
KW - Combination therapy
KW - Salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=33845574728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845574728&partnerID=8YFLogxK
U2 - 10.1002/cncr.22348
DO - 10.1002/cncr.22348
M3 - Article
C2 - 17103444
AN - SCOPUS:33845574728
VL - 107
SP - 2888
EP - 2897
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 12
ER -